论文部分内容阅读
目前,治疗消化道溃疡主要使用西咪替丁类H_2受体阻断剂,以抑制组胺诱导产生胃酸。可是,胃肠溃疡的发病机理与其他因素,如粘膜受到严重损害因而使抵抗力下降等,也有一定的关系。相对而言,对通过增强防御能力(如刺激氨基葡萄糖合成酶的增加来提高粘膜的抵抗力。而不是抑制进攻机制)这类药的研究注意不够,为此Ucker等人报道了5-[(2-二乙胺基)乙基]氨基-5,11-二氢[1]苯并氧杂环庚烷并[3,4-6]吡啶·三盐酸化物,即KW5805.早期的动物研究表明,KW5805具有保护粘膜的作用,因而能抵御广谱的实验性诱导产生的胃肠损害,已在自愿者身上对其进
At present, the treatment of peptic ulcer mainly uses cimetidine H 2 receptor blockers to inhibit histamine-induced gastric acid production. However, the pathogenesis of gastrointestinal ulcers and other factors, such as mucosal damage suffered so that the decline in resistance, but also a certain relationship. In contrast, less attention has been paid to the study of such drugs by enhancing the defense ability (such as increasing the mucosal resistance rather than inhibiting the attack mechanism) by increasing the defense capacity, for which Ucker et al. Reported 5 - [( 2-diethylamino) ethyl] amino-5,11-dihydro [1] benzoxepin [3,4-6] pyridine · trihydrochloride, ie, KW5805. Early animal studies have shown that , KW5805 protects the mucous membrane and thus protects against gastrointestinal damage caused by a broad spectrum of experimental inducements